Why is Aarti Drugs Ltd falling/rising?

Recent Price Movement and Market Context

The stock has been under pressure for several sessions, with a consecutive three-day decline resulting in a cumulative loss of 3.27%. On the day in question, Aarti Drugs opened sharply lower, down 6.63%, and touched an intraday low of ₹342.65, signalling strong selling interest. This underperformance extended beyond the single day, as the stock has lagged its sector by 2.35% and the broader Sensex index by a wider margin over the past month and year. Specifically, over the last month, the stock fell 6.74%, significantly worse than the Sensex’s 1.75% decline, while year-to-date losses stand at 13.17%, more than double the benchmark’s 5.85% fall.

Technically, the stock is trading below all key moving averages—5-day, 20-day, 50-day, 100-day, and 200-day—indicating a sustained bearish trend. Despite a rise in delivery volume by 10.66% on 27 Feb compared to the five-day average, suggesting increased investor participation, the selling pressure has outweighed buying interest, contributing to the price weakness.

Fundamental Performance and Profitability Concerns

While Aarti Drugs boasts a commendable management efficiency, reflected in a robust Return on Capital Employed (ROCE) of 15.44%, and maintains a relatively low average debt-to-equity ratio of 0.46 times, these positives have not translated into consistent profit growth. Over the past five years, the company’s operating profit has contracted at an annualised rate of 8.44%, signalling challenges in sustaining earnings momentum.

Quarterly financials reveal further strain. The company’s Profit After Tax (PAT) for the latest quarter stood at ₹40.54 crore, marking a steep decline of 18.6% compared to the average of the previous four quarters. Concurrently, interest expenses have surged to a quarterly high of ₹9.29 crore, while the operating profit to interest coverage ratio has dropped to a low of 5.92 times, indicating increased financial burden and reduced cushion to service debt.

Despite a profit rise of 32.7% over the past year and an attractive valuation with an enterprise value to capital employed ratio of 1.9, the stock’s price appreciation has been muted, delivering a modest 1.59% return over 12 months. This pales in comparison to the broader market’s gains, with the Sensex rising 9.62% and the BSE500 index up 14.43% over the same period. The company’s PEG ratio of 0.5 suggests undervaluation relative to earnings growth, but this has not been sufficient to offset concerns about profitability and growth sustainability.

Market Sentiment and Investor Outlook

The stock’s underperformance relative to both sector and market benchmarks, combined with deteriorating quarterly earnings and rising interest costs, has dampened investor sentiment. The presence of promoter majority shareholders provides some stability, but the weak long-term growth trajectory and recent financial pressures have weighed heavily on the share price.

Conclusion

In summary, Aarti Drugs Ltd’s recent share price decline on 02-Mar is primarily attributable to disappointing quarterly earnings marked by falling PAT and rising interest expenses, compounded by a weak five-year operating profit growth trend. The stock’s persistent underperformance against key indices and sector peers, alongside technical indicators signalling bearish momentum, have further contributed to negative market sentiment. While the company retains some fundamental strengths such as efficient capital utilisation and low leverage, these have not been sufficient to counterbalance the challenges faced, resulting in the current downward pressure on the stock price.

Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →